Bespoke Gene Therapy Consortium

organization

Last mentioned: Feb 24, 2026

Timeline

  1. Formal Proposal

    FDA formally proposes the new customized drug approval system for ultra-rare diseases.

  2. BGTC Pilot Completion

    The Bespoke Gene Therapy Consortium completes its first round of pilot manufacturing runs.

  3. Draft Guidance Issued

    FDA releases initial thoughts on 'n-of-1' therapy development and manufacturing.

  4. PREVENT Act Passed

    Congress directs FDA to establish a framework for platform technology designations.

Stories mentioning Bespoke Gene Therapy Consortium 1

fda-approval Bullish

FDA Unveils 'Platform' Pathway to Accelerate Bespoke Rare Disease Therapies

The FDA has proposed a landmark regulatory framework to streamline the approval of customized, 'n-of-1' therapies for ultra-rare diseases. By shifting focus from individual products to validated manufacturing platforms, the agency aims to drastically reduce the time and cost of bringing genetic treatments to patients with unique mutations.

2 sources